EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models

Tizong Miao, Alistair Symonds, Oliver J Hickman, Dongsheng Wu, Ping Wang, Nick Lemoine, Yaohe Wang iD, Spiros Linardopoulos, Gunnel Halldén iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25021265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Tizong Miao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. Hauptthemen laut MEDLINE: Oncolytic Viruses, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Oncolytic Virotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pancreatic Cancer Research Fund, BCI CRUK Centre Grant, UK charity Pancreatic Cancer Research Fund (PCRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive type of pancreatic cancer, which rapidly develops resistance to the current standard of care. Several oncolytic Human AdenoViruses (HAdVs) have been reported to re-sensitize drug-resistant cancer cells and in combination with chemotherapeutics attenuate solid tumour growth. Obstacles preventing greater clinical success are rapid hepatic elimination and limited viral replication and spread within the tumour microenvironment. We hypothesised that higher intratumoural levels of the virus could be achieved by altering cellular epigenetic regulation. Here we report on the screening of an enriched epigenetics small molecule library and validation of six compounds that increased viral gene expression and replication. The greatest effects were observed with three epigenetic inhibitors targeting bromodomain (BRD)-containing proteins. Specifically, BRD4 inhibitors enhanced the efficacy of Ad5 wild type, Ad∆∆, and Ad-3∆-A20T in 3-dimensional co-culture models of PDAC and in vivo xenografts. RNAseq analysis demonstrated that the inhibitors increased viral E1A expression, altered expression of cell cycle regulators and inflammatory factors, and attenuated expression levels of tumour cell oncogenes such as c-Myc and Myb. The data suggest that the tumour-selective Ad∆∆ and Ad-3∆-A20T combined with epigenetic inhibitors is a novel strategy for the treatment of PDAC by eliminating both cancer and associated stromal cells to pave the way for immune cell access even after systemic delivery of the virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirusesPancreatic NeoplasmsCarcinoma, Pancreatic DuctalOncolytic VirotherapyHumansNuclear ProteinsEpigenesis, GeneticTranscription FactorsCell Line, TumorAdenoviridaeTumor MicroenvironmentBromodomain Containing ProteinsCell Cycle Proteins

Stichwörter der Autor:innen

BRD4 inhibitorsNeo-273OTX-015co-culturesiBET-762in vivooncolytic adenovirusorganoid culturessmall molecule screenstromal cells

Substanzen

Nuclear ProteinsTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle Proteins

Autor:innen und Institutionen

  • Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
  • Cancer Drug Target Discovery Laboratory, The Institute of Cancer Research, London SW3 6JB, UK.
  • Bioimaging Centre, School of Engineering and Materials Science, Queen Mary University of London, London E1 4NS, UK.

ORCID-Profile: Yaohe Wang, Gunnel Halldén

Förderung

  • Pancreatic Cancer Research Fund
  • BCI CRUK Centre Grant
  • UK charity Pancreatic Cancer Research Fund (PCRF)

Zitieren

APA

Miao, T., Symonds, A., Hickman, O. J., Wu, D., Wang, P., Lemoine, N., Wang, Y., Linardopoulos, S., & Halldén, G. (2024). Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021265

Vancouver

Miao T, Symonds A, Hickman OJ, Wu D, Wang P, Lemoine N, et al. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25021265

BibTeX
@article{Miao2024,
  author = {Miao, Tizong and Symonds, Alistair and Hickman, Oliver J and Wu, Dongsheng and Wang, Ping and Lemoine, Nick and Wang, Yaohe and Linardopoulos, Spiros and Halldén, Gunnel},
  title = {Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25021265}
}
Kostenlos starten →